323 related articles for article (PubMed ID: 22301101)
21. Bortezomib: a valuable new antineoplastic strategy in multiple myeloma.
Bladé J; Cibeira MT; Rosiñol L
Acta Oncol; 2005; 44(5):440-8. PubMed ID: 16118077
[TBL] [Abstract][Full Text] [Related]
22. "Short course" bortezomib plus melphalan and prednisone as induction prior to transplant or as frontline therapy for nontransplant candidates in patients with previously untreated multiple myeloma.
Gasparetto C; Gockerman JP; Diehl LF; de Castro CM; Moore JO; Long GD; Horwitz ME; Keogh G; Chute JP; Sullivan KM; Neuwirth R; Davis PH; Sutton LM; Anderson RD; Chao NJ; Rizzieri D
Biol Blood Marrow Transplant; 2010 Jan; 16(1):70-7. PubMed ID: 19733251
[TBL] [Abstract][Full Text] [Related]
23. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression.
Mateos MV; Hernández JM; Hernández MT; Gutiérrez NC; Palomera L; Fuertes M; Garcia-Sanchez P; Lahuerta JJ; de la Rubia J; Terol MJ; Sureda A; Bargay J; Ribas P; Alegre A; de Arriba F; Oriol A; Carrera D; García-Laraña J; García-Sanz R; Bladé J; Prósper F; Mateo G; Esseltine DL; van de Velde H; San Miguel JF
Haematologica; 2008 Apr; 93(4):560-5. PubMed ID: 18322252
[TBL] [Abstract][Full Text] [Related]
24. Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment.
Tai YT; Li XF; Breitkreutz I; Song W; Neri P; Catley L; Podar K; Hideshima T; Chauhan D; Raje N; Schlossman R; Richardson P; Munshi NC; Anderson KC
Cancer Res; 2006 Jul; 66(13):6675-82. PubMed ID: 16818641
[TBL] [Abstract][Full Text] [Related]
25. [The mechanisms of drug resistance via the interaction of myeloma cells with stromal cells].
Kikuchi J; Furukawa Y
Nihon Rinsho; 2015 Jan; 73(1):57-61. PubMed ID: 25626305
[TBL] [Abstract][Full Text] [Related]
26. Combined proteasome and histone deacetylase inhibition: A promising synergy for patients with relapsed/refractory multiple myeloma.
Jagannath S; Dimopoulos MA; Lonial S
Leuk Res; 2010 Sep; 34(9):1111-8. PubMed ID: 20472288
[TBL] [Abstract][Full Text] [Related]
27. [Treatment with a proteasome inhibitor, bortezomib, for thalidomide-resistant multiple myeloma].
Takatoku M; Noborio-Hatano K; Takahashi S; Kikuchi S; Mori M; Muroi K; Komatsu N; Ozawa K
Rinsho Ketsueki; 2004 Feb; 45(2):144-8. PubMed ID: 15045823
[TBL] [Abstract][Full Text] [Related]
28. Bortezomib in the front-line treatment of multiple myeloma.
Richardson PG; Mitsiades C; Schlossman R; Ghobrial I; Hideshima T; Munshi N; Anderson KC
Expert Rev Anticancer Ther; 2008 Jul; 8(7):1053-72. PubMed ID: 18588451
[TBL] [Abstract][Full Text] [Related]
29. Hepatic plasmacytosis as a manifestation of relapse in multiple myeloma treated with thalidomide.
del Giglio A; Weinschenker P; Manhani AR; Carbonell AL; Mitteldorf CA
South Med J; 2005 Feb; 98(2):238-40. PubMed ID: 15759959
[TBL] [Abstract][Full Text] [Related]
30. Ectopic cyclin D1 overexpression increases chemosensitivity but not cell proliferation in multiple myeloma.
Kuroda Y; Sakai A; Tsuyama N; Katayama Y; Munemasa S; Asaoku H; Okikawa Y; Nakaju N; Mizuno M; Ogawa K; Nishisaka T; Matsui H; Tanaka H; Kimura A
Int J Oncol; 2008 Dec; 33(6):1201-13. PubMed ID: 19020753
[TBL] [Abstract][Full Text] [Related]
31. [Treatment of multiple myeloma].
Terriou L; Leleu X; Yakoub-Agha I
Bull Cancer; 2006 Jan; 93(1):101-6. PubMed ID: 16455512
[TBL] [Abstract][Full Text] [Related]
32. Clinical management of myeloma--state of the art.
Harousseau JL
Cancer Treat Rev; 2010 May; 36 Suppl 2():S1-2. PubMed ID: 20472182
[TBL] [Abstract][Full Text] [Related]
33. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.
Pei XY; Dai Y; Grant S
Clin Cancer Res; 2004 Jun; 10(11):3839-52. PubMed ID: 15173093
[TBL] [Abstract][Full Text] [Related]
34. Management of older patients with multiple myeloma.
Gay F; Palumbo A
Blood Rev; 2011 Mar; 25(2):65-73. PubMed ID: 21295387
[TBL] [Abstract][Full Text] [Related]
35. Bone marrow angiogenesis and angiogenic factors in multiple myeloma treated with novel agents.
Cibeira MT; Rozman M; Segarra M; Lozano E; Rosiñol L; Cid MC; Filella X; Bladé J
Cytokine; 2008 Mar; 41(3):244-53. PubMed ID: 18178097
[TBL] [Abstract][Full Text] [Related]
36. Suitable drug combination with bortezomib for multiple myeloma under stroma-free conditions and in contact with fibronectin or bone marrow stromal cells.
Kikuchi J; Koyama D; Mukai HY; Furukawa Y
Int J Hematol; 2014 Jun; 99(6):726-36. PubMed ID: 24706190
[TBL] [Abstract][Full Text] [Related]
37. Novel therapeutic avenues in myeloma: changing the treatment paradigm.
Ghobrial J; Ghobrial IM; Mitsiades C; Leleu X; Hatjiharissi E; Moreau AS; Roccaro A; Schlossman R; Hideshima T; Anderson KC; Richardson P
Oncology (Williston Park); 2007 Jun; 21(7):785-92; discussion 798-800. PubMed ID: 17722741
[TBL] [Abstract][Full Text] [Related]
38. [Advances in therapeutic strategies for multiple myeloma].
Miwa A
Gan To Kagaku Ryoho; 2007 Dec; 34(13):2200-16. PubMed ID: 18079620
[TBL] [Abstract][Full Text] [Related]
39. [Prognostic significance of morphology in multiple myeloma].
Al-Sahmani M; Trnavská I; Antošová M; Antošová L; Kissová J; Kaisarová B; Adam Z; Buliková A; Penka M; Hájek R
Klin Onkol; 2012; 25(2):103-9. PubMed ID: 22533884
[TBL] [Abstract][Full Text] [Related]
40. The effects of bortezomib on bone disease in patients with multiple myeloma.
Mohty M; Malard F; Mohty B; Savani B; Moreau P; Terpos E
Cancer; 2014 Mar; 120(5):618-23. PubMed ID: 24249482
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
